- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01960231
The Effect of ß-cell Specific Glucokinase Mutation on Glucose Homeostasis and Insulin Secretion in a MODY-2 Family
Type 2 diabetes mellitus patients exhibit many glucose homeostasis abnormalities in different tissues and organs. Among the more important defects are disturbed hepatic glucose metabolism and defective pancreatic β-cell function. Hexokinase IV, commonly known as glucokinase, is the predominant hexokinase expressed in the liver, the pancreatic β-cells (where it functions as the glucose sensor for insulin secretion) and in glucose-sensory cells in the hypothalamus and gut.
The glucokinase gene contains two distinct promoters. The downstream one is active only in hepatocytes and the upstream promoter is active only in extrahepatic glucose sensory-cells. Alternative promoters enable differential regulation of gene transcription in liver and extrahepatic sites. In pancreatic β-cells, glucokinase expression at the mRNA level is largely constitutive, whereas in the liver it undergoes large adaptive changes in response to nutritional states, enabling larger changes in glucokinase activity than would otherwise be possible by post-transcriptional regulation alone.
Most of the MODY-2 patients were found to have glucokinase mutations located in areas that are common to the liver and pancreas. The diabetes in these patients is related both to defect in insulin secretion and abnormal hepatic glucose metabolism. Point mutation in the pancreatic specific promoter was recently described as a cause for impaired fasting glucose [Diabetes 58:1929-1935, 2009]. The investigator have recently identified a MODY-2 family with a genetic defect that is located in the pancreatic promoter, sparing the liver promoter. This family demonstrates that abnormal insulin secretion alone (perhaps together with other extrahepatic glucose sensors) is enough to cause diabetes.
In this study, the investigators would like to use an oral glucose tolerance test (OGTT) and continuous glucose monitoring (CGM) technique in order to elucidate the relative roll of the hepatic glucokinase in normal glucose homeostasis. This issue is complicated by the fact that in addition to glucokinase, hexokinase isoenzymes I, II and III are also expressed at very low levels in hepatocytes. They are an important back-up mechanism when glucokinase activity is compromised, as in liver cirrhosis or murine models with liver-specific glucokinase knock-down. However, impaired hepatic glycogen synthesis was demonstrated in MODY-2 subjects (JCI 1996:98:1755). By comparing members of the investigators MODY-2 family with members of other MODY-2 families and normal controls the investigators hope to shade some light on this question.
Study Overview
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Jacob Ilany, MD
- Phone Number: 972-3-5302021
- Email: jacob.ilani@sheba.health.gov.il
Study Locations
-
-
-
ramat Gan, Israel, 52621
- Recruiting
- Sheba Medical Center
-
Contact:
- Ayana Paster, RD
- Phone Number: 972-3-5302021
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- MODY 2 patients with documented mutations in the glucokinase promoter or coding region.
- Healthy non-diabetic individuals matched for age, sex and BMI with recruited MODY2 patients.
- Age range - 12-80; males and females
Exclusion Criteria:
- Unable to provide written informed consent.
- Unable to safely stop glycemia related medications for the duration of the test + wash-out period.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
pancreas specific MODY-2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
fasting and post glucose load glucose level
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
fasting and post glucose load Insulin
Time Frame: 1 year
|
1 year
|
fasting and post glucose load c-peptide
Time Frame: 1 year
|
1 year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
glucose metabolism measured by CGMS
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jacob Ilany, MD, Sheba Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SHEBA-13-0464-JI-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MODY-2 Diabetes
-
Steno Diabetes Center GreenlandUniversity of Southern DenmarkCompletedType 2 Diabetes | MODYGreenland
-
University of OxfordOxford University Hospitals NHS TrustCompleted
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
United Arab Emirates UniversityNot yet recruitingMaturity-onset Diabetes of the Young | MODY | Monogenic Diabetes
-
Castilla-La Mancha Health ServiceRecruiting
-
Imperial College London Diabetes CentreUnknownGestational Diabetes | Maturity-onset Diabetes of the Young | GDM | MODYUnited Arab Emirates
-
Université Catholique de LouvainCompletedDiabetes Mellitus | MODYBelgium
-
Indonesia UniversityRecruiting
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
Clinical Trials on OGTT
-
Institut de Recherches Cliniques de MontrealVertex Pharmaceuticals Incorporated; Université de MontréalCompletedCystic Fibrosis | Cystic Fibrosis-related DiabetesCanada
-
Universidad de MurciaUnknownNon-Diabetic Disorder of Endocrine PancreasSpain
-
Odense University HospitalUniversity of Southern Denmark; Region of Southern Denmark; Municipality of OdenseCompletedPolycystic Ovary Syndrome | Gestational Diabetes MellitusDenmark
-
Glostrup University Hospital, CopenhagenCompletedDiabetes MellitusDenmark
-
University of MinnesotaMayo ClinicCompleted
-
Peking University First HospitalCompletedDiabetes | Gestational Diabetes | Macrosomia, Fetal
-
Ullevaal University HospitalUnknownMyocardial Infarction | Inflammation | Type 2 Diabetes | Impaired Glucose ToleranceNorway
-
Sint Franciscus GasthuisCompletedType 2 Diabetes Mellitus | Atherosclerosis | Leukocyte Activation Disorder | Familial Combined Hyperlipidemia
-
Xuewen WangCompleted
-
University of AberdeenRecruiting